Advertisement
Screener

REPLIGEN CORP (RGEN) Form D

REPLIGEN CORP Form D Notices of Exempt Offering of Securities

Notices filed with the SEC for securities sold without registration under Regulation D or Section 4(a)(5), newest first. Values are as filed.

  • 2019-06-13: Federal exemption Rule 506(b); Types of securities offered Equity; Date of first sale 2019-05-31; Total offering amount $48,000,000.
  • 2017-08-08: Federal exemption Rule 506(b); Types of securities offered Equity; Date of first sale 2017-08-01; Total offering amount $238,590,580.
  • 2014-06-16: Federal exemption Rule 506(b); Types of securities offered Equity; Date of first sale 2014-06-02; Total offering amount $4,000,000.
FiledFederal exemptionTypes of securities offeredDate of first saleTotal offering amountTotal amount soldTotal remaining to be soldInvestors who have already invested
2019-06-13Rule 506(b)Equity2019-05-31$48,000,000$48,000,000$01
2017-08-08Rule 506(b)Equity2017-08-01$238,590,580$238,590,580$08
2014-06-16Rule 506(b)Equity2014-06-02$4,000,000$4,000,000$01

Similar stocks

Stock NameCountryMarket CapPE Ratio
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
EXELIXIS, INC. (EXEL)United States$14.358B16.15
Immunovant, Inc. (IMVT)United States$7.028B-14.78